AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03699995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Procedure
Description: Undergo MoleMapper/Sklip app/native smartphone camera app imaging with smartphone
Study NCT03699995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Given SC
Study NCT03699995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch Biopsy
Description: Undergo punch biopsy
Study NCT03699995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shave Biopsy
Description: Undergo shave biopsy
Study NCT03494569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT03494569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03494569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given as per City of Hope Standard Operating Procedure
Study NCT03494569 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Undergo TMLI
Study NCT02317055 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: imaging
Study NCT03424590 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clearblue Connected Ovulation Test System
Description: Urinary LH test to predict ovulation
Study NCT02696564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated
Study NCT02696564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule per day for two weeks, followed by two capsules per day for 46 weeks
Study NCT01995448 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood test
Description: Residue of blood further to NFS.
Study NCT00993239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant (TL32711)
Description: 30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated
Study NCT00286208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone, misoprostol
Study NCT03166475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical procedures
Description: All the extractions were performed under local anaesthesia, minimally traumatic as possible. After the extraction, each patient was treated according to the group of their allocations.
Study NCT01819025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 face-to-face therapy session and a smartphone-app
Description: An 8 week blended therapy with both face-to-face therapy sessions and support through a smartphone application.
Study NCT01819025 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT, treatment as usual
Description: 10 sessions of face-to-face therapy, full behavioral activation
Study NCT04396041 — intervention group
Intervention type: DEVICE
Intervention: Microvascular Plug (MVP)
Description: Patient's Pulmonary AVM(s) treated via transcatheter embolization with Microvascular Plugs.
Study NCT04396041 — intervention group
Intervention type: DEVICE
Intervention: Amplatzer Vascular Plug (AVP)
Description: Patient's Pulmonary AVM(s) treated via transcatheter embolization with Amplatzer Vascular Plugs.
Study NCT04396041 — intervention group
Intervention type: DEVICE
Intervention: Detachable coils
Description: Patient's Pulmonary AVM(s) treated via transcatheter embolization with detachable coils.
Study NCT02295566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Not required
Study NCT02295566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Not required
Study NCT02105805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietetic group sessions
Description: Group sessions to improve dietary adherence
Study NCT02105805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietetic group sessions
Description: Group sessions to improve dietary adherence
Study NCT02766816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part 1 study - BBio bOPV
Description: A single dose of 2 drops (0.1 ml) orally of BBio bOPV to 20 children 60 to 83 months of age.
Study NCT02766816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part 2 study - BBio bOPV Lot 1
Description: Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 1 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
Study NCT02766816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part 2 study - BBio bOPV Lot 2
Description: Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 2 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
Study NCT02766816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part 2 study - BBio bOPV Lot 3
Description: Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 3 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
Study NCT02766816 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Part 2 study - Licensed bOPV
Description: Three doses of 2 drops (0.1 ml) orally of a licensed bOPV to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
Study NCT02766816 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Part 1 study - Licensed bOPV
Description: A single dose of 2 drops (0.1 ml) orally of a licensed bOPV to 20 children 60 to 83 months of age.
Study NCT03863522 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fine needle aspiration
Description: Fine needle aspiration is a type of biopsy procedure to diagnose suspicious lesions. After giving numbing medicine, a thin needle is inserted into the breast to obtain a sample. This procedure is followed by the standard of care and will last about 10 minutes. The sample will be analyzed by a diagnostic cartridge and by the cytopathologist.
Study NCT03863522 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cancer Detection cartridge
Description: The Cancer Detection cartridge has the ability to measure methylated gene changes in breast cells. The device will not be in contact with the patients. The FNA samples will be smeared on a slide which will be placed into the cartridge for analysis.
Study NCT03126864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: After enrollment, steady state leukapheresis performed to collect apheresis material. The goal is to achieve a target total nucleated cell (TNC) yield of at least 5 x 10\^9 (expected range 5 x 10\^8 - 5 x 10\^10), for up to two days.
Study NCT03126864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 administered by vein on Days -5 to -3.
Study NCT03126864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 900 mg/m2 administered by vein on Day -3.
Study NCT03126864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD33-CAR-T Cell Infusion
Description: CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found. Starting dose level is > 1.5 x 105/kg but ≤ 4.5 x 105/kg.
Study NCT00787319 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: Outpatients with age-related macular degeneration (AMD)
Study NCT01637701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PkEP
Description: Plasmakinetic enucleation of the prostate
Study NCT01637701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: B-TURP
Description: Bipolar transurethral resection of the prostate
Study NCT05038852 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: smartphone applications
Description: app is designed to help you learn relaxation skills.
Study NCT01873573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dilation
Description: Dilation will be performed by either dilation balloons or over the wire polyvinyl dilators based upon the physician's discretion. Fluoroscopy may be used to aid in endoscopic dilation at the physician's discretion.
Study NCT01873573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Injection
Description: Triamcinolone is a generic name of a long-acting synthetic corticosteroid and approved for sale in the United States by the U.S. Food and Drug Administration (FDA). After endoscopic dilation is performed, a total of 40-80 mg (physician preference) of triamcinolone (40 mg/ml) will be injected throughout the stricture under direct visualization.
Study NCT04130542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LVGN6051
Description: IV infusion once every 3 weeks (Q3W).
Study NCT04130542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KEYTRUDA® (pembrolizumab)
Description: IV infusion once every 3 weeks (Q3W).
Study NCT05038852 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: smartphone applications
Description: app is designed to help you increase your positive feelings, behaviors, and thoughts.
Study NCT03324464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Central Executive Training: Working Memory
Description: Computerized working memory training
Study NCT03324464 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Central Executive Training: Inhibitory Control
Description: Computerized inhibitory control training
Study NCT05040607 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: The first stage of the study:~Retrospective data collection of pulmonary function, respiratory muscle strength, exercise capacity, physical fitness, and activities of daily living (ADL).~The second stage of the study~-Retrospective data of pulmonary function, respiratory muscle function, functional capacity before and after supervised inspiratory muscle training with POWERbreathe K5 device using tapered flow resistive loading and airway clearance techniques performed for 6 weeks in PCD with decreased respiratory muscle strength.
Study NCT05040607 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: -Retrospective data collection of pulmonary function, respiratory muscle function, exercise capacity, physical fitness, and activities of daily living (ADL).
Study NCT01567332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Active coil
Description: For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions.
Study NCT01567332 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SHAM inactive - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Inactive coil
Description: For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions.
Study NCT03987425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: In this group of patients (CPAP group) will be prescribed CPAP treatment at optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
Study NCT01993459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: We will administer Midazolam 3mg intravenously once pre-operatively to patients just before they undergo surgery
Study NCT01993459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (sodium chloride) 0,9%
Description: We will administer NaCl (sodium chloride) 0,9% 3ml intravenously once pre-operatively to patients just before they undergo surgery
Study NCT02932059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metamemory
Description: Metamemory evaluation using a sentence construction strategy
Study NCT00792103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101
Description: NP101 study patch 4 hour application
Study NCT03715400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Virtual Reality Training
Description: Participants will undergo 7 45 minute sessions of positive virtual reality training over the course of four weeks. All assessments will be completed online at home following initial orientation to the program.
Study NCT02640443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole
Description: 60 mg sulfamethoxazole per kg bodyweight (maximal of 3g) divided in 2 doses per day during 3 weeks
Study NCT00749125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: 10 mg by mouth once per day for first 2 weeks, with psychiatric re-evaluation every 2 weeks to determine if any change in dosage is required, with a maximum of 20 mg per day
Study NCT01920425 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Kinesia HomeView
Description: Motion sensor based telemedicine system for assessment of movement disorder motor symptoms in the home. Includes automated motor assessment using motion sensor and electronic dyskinesia diary.
Study NCT01920425 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hand-written diary
Description: Hand-written paper diary indicating state (Off, On without dyskinesias, on with non-troublesome dyskinesias, on with troublesome dyskinesias) at 30 minute intervals.
Study NCT04402463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation
Description: The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~In the treatment 3 of the therapeutic postures of GPR method to will carry out following Souchard's principles of Global Postural Reeducation
Study NCT02057484 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus
Description: oral
Study NCT04402463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapeutic
Description: The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~The treatment will be divided into 3 phases, where it initially starts with phase 1 (3 treatments) and progresses to phase 2 (3 treatments) until reaching stage 3 (2 treatments).
Study NCT01756261 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Patients treated with EYLEA under practical manner for AMD.
Study NCT04167995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Formula lacteal forte
Description: Active Comparator: Patient with attention deficit hyperactive disorder patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
Study NCT04555096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419
Description: 180 Minute IV Infusion
Study NCT04555096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 180 Minute IV Infusion
Study NCT04322006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ004309
Description: Antibody to CD73
Study NCT04322006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Humanized monoclonal antibody to PD-1
Study NCT01873573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD)
Description: EGD is a test to examine the lining of the esophagus (the tube that connects your throat to your stomach), stomach, and first part of the small intestine. It is done with a small camera (flexible endoscope) that is inserted down the throat.
Study NCT03452488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO101
Description: Oral capsules
Study NCT03452488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules
Study NCT04009668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab will be dosed based on weight
Study NCT04168502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Patients will receive induction and consolidation with Gemtuzumab ozogamicin, Daunorubicin and Cytarabine
Study NCT01159990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5 Gag-Pol Env A/B/C
Description: 1×10\^10 particle units (PU) rAd5 Gag-Pol, Env A/B/C (3:1:1:1 mixture) delivered via intramuscular injection
Study NCT00692471 — intervention group
Intervention type: DEVICE
Intervention: Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter
Description: Watch to be worn on wrist for 7 days (except in water) that will measure activity/movement.
Study NCT03583541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Risk Reduction
Description: This is an intervention comprised of 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention.
Study NCT03583541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Literacy
Description: This evidence-based Financial Education Core Curriculum addresses the importance of savings, banking services, budgeting debt management. Undarga adaptation for FSWs included shortening and simplifying sessions while retaining core elements; adding weekly check-ins due to safety concerns FSWs share related to intervention participation, and safety planning as needed. We will further adapt sessions in months 1-6 to assure language and illustrative examples are culturally consonant, and to infuse BE principles consistent with HIVRR. During sessions 1 \& 2 we will include information on delay discounting, for example, learning to understand the tendency to prefer small immediate rewards over larger available at a later time; sessions 3 \& 4 will include details on economic utility; sessions 5 will contain information on salience (e.g. understanding occasions when women may minimize triggers to unsafe sex); and session 6 will address loss aversion.
Study NCT01159990 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rAd5 Gag-Pol
Description: 5×10\^9 PU rAd5 Gag-Pol delivered via intramuscular injection
Study NCT02210611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine Insemination 36 hours
Description: Intrauterine insemination 36 hours after ovulation induction
Study NCT02210611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine Insemination 42 hours
Description: Intrauterine insemination 42 hours after ovulation induction
Study NCT03583541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentorship
Description: Mentorship. Mentorship to bridge the transition from FL and savings to a vocational change is a critical component of this intervention. These sessions are intended to support the transition -equipped with financial literacy and savings -to vocational, educational, employment or small business development training using matched savings. The mentorship sessions are adapted from the pilot study and integrate components (e.g., referral and linkage, coaching, exchange visits to model farmers) from income-generating activities provided by our collaborating partner, RTY. All sessions include check-in and individual attention. The first 4 sessions focus on identifying options for vocational, educational, employment or business development training. The second 4 sessions include invited experts in identified areas of interest by group members for more intensive time and attention to individualized needs to make the transition.
Study NCT03583541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Matched savings individual development account
Description: A matched savings individual development account (hereafter IDA) is a savings account held at a local bank whereby deposits made by the woman are matched by the intervention to encourage savings and investment in skills and asset development. The accounts introduce women to financial management skills, introduce them to formal financial institutions, and by matching their deposits, incentivize women to save small amounts. Each woman will receive an IDA held in her own name. Women will be allowed and indeed encouraged to contribute up to 50,000 shillings (\~15 USD) per month towards their IDAs. The maximum amount of women's contribution to be matched will be an equivalent of US$15 per month for 10 months. During the intervention, monthly account statements will be generated for women to note their accumulated savings. During the intervention, women will have direct access to both their personal savings deposited in the accounts and the match provided by the study.
Study NCT04045821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Description: Subjects in this arm will have AMD3100 administered per the standard dosing regimen of 0.24 mg/kg actual body weight subcutaneous x1 dose
Study NCT04045821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Subjects in this arm will have a placebo of normal saline administered subcutaneously x1 dose
Study NCT04045821 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: dilation and curettage
Description: all participants will undergo routine D\&C procedure